Karvil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Karvil

Quick Facts

Property Description
Active ingredient Carvedilol (INN)
Form Film-coated tablet
Pharmacological class Adrenergic Antagonist (Beta-blocker and Alpha-1 blocker)
Common use Supporting cardiovascular stability
Origin Synthetic, carbazole derivative

What is the Medicine Karvil?

Karvil is a prescription-only cardiovascular medication whose active component is Carvedilol, a synthetic compound utilized to manage the stability of the heart and circulatory system. It is defined as a single-ingredient product, chemically originating as a carbazole and propanol derivative. The medication is administered via the oral route, typically supplied as a film-coated tablet. It is classified as an alpha- and beta-adrenoreceptor blocking agent, indicating its comprehensive action on nervous system signals that regulate the heart and blood vessels.

Karvil’s Pharmacological Classification and Composition

Karvil is precisely categorized as an Adrenergic Antagonist with a dual-action mechanism, functioning as both a non-selective beta-blocker and an alpha-1 blocker. This dual functionality enables the management of stress hormone activity in both the heart and peripheral vessels. This feature indicates the drug helps to moderate the heart's activity while simultaneously promoting necessary relaxation of blood vessels, a characteristic that distinguishes it from older, pure beta-blockers. The active substance, Carvedilol, is manufactured as a racemic mixture integrated into a solid tableting matrix with pharmaceutical excipients.

High-Level Purpose and Therapeutic Action

The general purpose of Karvil is to improve cardiac function by reducing the overall strain placed on the heart and circulatory system. It achieves this by simultaneously moderating the heart rate and contraction force and producing a peripheral vasodilating effect that helps to lower vascular resistance. This combined approach is fundamental to achieving hemodynamic balance and stability, a mechanism utilized in the management of sustained high blood pressure. Carvedilol also possesses antioxidant properties, a distinguishing feature that provides additional protection to the heart and blood vessels.

Regulatory References

  1. National Institutes of Health (NIH) research

What side effects are possible with Karvil?

Possible Side Effects and Safety Information

The official safety profile for Karvil (Carvedilol) organizes potential adverse reactions according to the frequency with which they have been observed in clinical use, based on documentation from regulatory authorities such as the FDA and the EMA.

Documented Adverse Reactions and Frequencies

Classification Examples of Documented Effects System-Organ Class
Very Common (ge 10%) Dizziness, Fatigue (Asthenia) Nervous System, General Disorders
Common (ge 1% to < 10%) Hypotension (Low Blood Pressure), Bradycardia (Slow Heart Rate), Edema (Fluid Retention), Headache, Diarrhea Cardiovascular, Gastrointestinal, Metabolic
Uncommon (ge 0.1% to < 1%) Syncope (Fainting), Presyncope, Sleep disturbances Nervous System, Cardiovascular
Very Rare Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS) Skin and Subcutaneous Tissue

High-Level Safety Considerations

Specific safety characteristics are noted in official labeling. Effects like dizziness and syncope are documented as being more likely to occur upon treatment initiation and during dose increases, reflecting a time-dependent pattern. Use is contraindicated in individuals with severe hepatic impairment and bronchial asthma, due to the potential for increased drug exposure or exacerbation of underlying conditions. For patients with diabetes, the medication may mask the symptoms of hypoglycemia, and specialized monitoring is advised. A serious adverse reaction documented is the potential for worsening heart failure or the exacerbation of coronary artery disease if the medicine is abruptly discontinued.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Karvil (Carvedilol) may lead to severe, life-threatening physiological outcomes, primarily related to its profound circulatory effects. Documented manifestations include Severe Hypotension (dangerously low blood pressure) and marked Bradycardia (slow heart rate). Neurological signs such as Lapses of consciousness, Dizziness, Fainting, and Generalized Seizures are also explicitly listed in official product labeling. Severe respiratory problems, including Bronchospasm, are classified as serious potential outcomes.

A severe overdose is classified as potentially life-threatening due to the risk of progression to Cardiogenic Shock and Cardiac Arrest. Emergency regulatory statements mandate that the individual or caregiver must seek immediate medical attention and call emergency services immediately if the patient has collapsed, has trouble breathing, or cannot be awakened. Contacting a Poison Control Center is required in all suspected cases.

Management of overdose is strictly supportive and symptomatic, as no specific antidote is documented in the official prescribing information. Required procedural steps include mandatory hospital monitoring, continuous checking of vital signs, administration of Activated Charcoal, and the use of medications like vasopressors or glucagon to support cardiac function. Furthermore, low blood sugar (hypoglycemia) is noted as a specific manifestation common in children following this type of overdose exposure.

Therapeutic Uses of Karvil

What Karvil Treats: Main Uses and Benefits

Karvil (Carvedilol) is a long-term supportive medication applied across domains where additional symptomatic support is needed for chronic cardiovascular conditions. The medication is relevant for easing symptoms associated with long-standing heart issues. Its primary uses include the management of Chronic Heart Failure (CHF), Essential Hypertension (sustained high blood pressure), and the stabilization of Left Ventricular Dysfunction following a heart attack.

The medication helps address symptoms related to systemic imbalance, such as undue fatigue and shortness of breath associated with CHF, or the noticeable physiological strain caused by high vascular pressure. It is generally applied to provide supportive relief during phases when symptoms become more noticeable, assisting with managing high vascular pressure and contributing to easing the overall symptom load. For many patients, the medicine is considered relevant for easing discomfort during episodes of heightened distress.

“This medication is commonly used to help patients cope more steadily with symptom fluctuations in chronic heart disease.”


Quick Fact: Relevant for Easing Vascular Strain

Key Therapeutic Domains

  • Chronic Heart Failure Symptoms: Karvil is generally applied as an adjunctive treatment to help ease the overall symptom burden and may assist with maintaining functional stability in patients experiencing symptoms related to systemic imbalance.
  • Sustained High Blood Pressure (Hypertension): The medication assists with managing high vascular pressure, helping address groups of symptoms that may become disruptive. It is applied in addressing sustained physiological stress.
  • Stabilization After a Heart Attack: In situations where patients experience cardiac events, its supportive use is considered relevant for maintaining functional stability and supports general well-being during the recovery phase.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Karvil (Carvedilol) is a beta-blocker medication prescribed for conditions such as heart failure, high blood pressure (hypertension), and left ventricular dysfunction following a heart attack. It is generally safe for most adults when used as directed.


Contraindications (Who Should Not Use Karvil)

Karvil is contraindicated and should not be used in people with certain serious medical conditions, including:

  • Bronchial Asthma or related bronchospastic conditions, as the medication can worsen breathing difficulties.
  • Severe Liver Impairment, because the drug is processed by the liver, and severe impairment can lead to dangerously high levels in the body.
  • Serious Heart Conditions such as Second- or Third-Degree Atrioventricular (AV) Block, Sick Sinus Syndrome (unless a permanent pacemaker is in place), Severe Bradycardia (very slow heart rate), or Decompensated Heart Failure requiring intravenous medication to support the heart.
  • A known allergy or hypersensitivity to Carvedilol or any components of the tablet.

Precautions (Use with Caution)

Certain conditions require cautious use and close monitoring by a healthcare provider, including diabetes (as Karvil can mask signs of low blood sugar), peripheral vascular disease, and thyroid disorders (such as hyperthyroidism).

What should I know about interactions with other medicines?

Karvil Interactions with other medicines and products

The interaction profile of Karvil (Carvedilol) is primarily defined by pharmacokinetic modulation and additive pharmacodynamic effects, as documented in official regulatory labeling. Co-administration with certain substances can significantly alter Karvil's exposure. For instance, strong CYP2D6 inhibitors (e.g., Fluoxetine, Amiodarone) may increase Karvil's plasma levels, potentially leading to enhanced effects. Conversely, Rifampin, a potent enzyme inducer, is documented to reduce Karvil exposure (AUC and Cmax) by approximately 70%.

Pharmacodynamic and Transporter Interactions

Additive effects are noted with other agents that lower heart rate or blood pressure. Co-administration with Digoxin or other hypotensive agents (e.g., Diuretics, Clonidine) may result in an increased risk of bradycardia or hypotension. Karvil also affects drug transport; it is documented to increase the blood concentrations of Cyclosporine by inhibiting P-glycoprotein-mediated transport. For administration, Karvil is subject to a timing requirement and must be taken with food to slow the rate of absorption and minimize the official risk of orthostatic hypotension.

Use of Karvil is contraindicated in patients with severe hepatic impairment as this condition significantly increases plasma concentrations due to reduced drug clearance.

Mechanism of Action

Dual-Action Blockade of Sympathetic Nervous System Receptors

Karvil's mechanism involves dual antagonism of adrenergic receptors: it blocks beta1-receptors in the heart, suppressing the effects of catecholamines by interrupting Gs-protein signaling. This results in negative chronotropy (slower rate) and negative inotropy (reduced force of contraction). Simultaneously, it blocks alpha1-receptors on peripheral blood vessels, preventing the signals that cause vascular smooth muscle constriction. This combined action ensures the reduction in cardiac workload is balanced by peripheral vasodilation, resulting in reduced total peripheral resistance (TPR).


Intrinsic Cellular Protection and Unique Receptor Modulation

Beyond receptor blocking, the molecule has intrinsic activity as an antioxidant that scavenges Reactive Oxygen Species (ROS) within cardiovascular tissues. It also acts as a beta-arrestin biased ligand at the beta2-receptor, promoting G-protein-independent signaling pathways. This ancillary mechanism of cellular protection and unique receptor modulation contributes to the preservation of myocardial and vascular cell integrity against oxidative stress.

Dosage and Administration Information

How to Use Karvil

The usage of Karvil (Carvedilol) tablets is defined by an oral, twice-daily administration schedule. The immediate-release tablet must be consumed with food to regulate the rate of absorption and standardize the systemic delivery of the active ingredient. The fundamental principle of its use is titration, meaning treatment begins with the lowest available dose, which is then systematically and gradually increased. This gradual adjustment is critical for establishing long-term administration.

Dosing Schedule and Titration

The schedule for increasing the dose is specific to the condition being managed. For Chronic Heart Failure, dose escalation occurs slowly, at intervals of at least two weeks, starting typically at 3.125 mg twice daily. For stabilizing Left Ventricular Dysfunction following a heart attack, the intervals are typically shorter, spanning 3 to 10 days. Conversely, for Hypertension, dose increases proceed over intervals of seven to fourteen days.

Administration Constraints

The maximum dose is subject to established limits; for example, the total daily dose for hypertension should not exceed 50 mg. Administration is governed by key physiological constraints: the medication is prohibited for use in patients with severe hepatic impairment, and for chronic heart failure, fluid retention must be minimized prior to initiating the titration process. The overall duration of use is defined as long-term therapy for chronic cardiovascular conditions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Karvil

This overview describes the official research evidence for Karvil (Carvedilol), focusing on the types of studies conducted, the outcomes they tracked, and the areas where evidence remains limited or uncertain, as reported in scientific literature and by regulatory bodies.


Evidence for use in Chronic Heart Failure (CHF)

Research for Karvil in Chronic Heart Failure involves multiple studies referenced by regulatory authorities. Randomized Controlled Trials (RCTs) have been conducted, often comparing Karvil against an inactive substance (placebo) in adults already receiving standard care. These studies focused on populations presenting with heart failure characterized by reduced heart function (low Left Ventricular Ejection Fraction, or LVEF). The main outcomes that researchers monitored included the tracking of long-term patient survival (all-cause mortality) and the frequency of hospitalization (due to worsening heart failure or cardiovascular issues).

Studies monitored the rates of cardiovascular hospitalization observed when Karvil was compared against a placebo. Research describes measurements of heart function observed during the study period. While research describes findings that were observed across multiple studies and different clinical settings, data for certain subgroups, such as children and adolescents, remain limited.


Evidence for use in Left Ventricular Dysfunction (LVD) Following a Heart Attack

Research has explored the role of Karvil in adults who experienced a heart attack (Myocardial Infarction or MI) and were subsequently found to have Left Ventricular Dysfunction (LVD). This evidence comes primarily from a large Randomized Controlled Trial (RCT). Research tracked outcomes related to long-term patient survival and the frequency of experiencing a subsequent non-fatal heart attack. Studies also tracked physiological parameters, such as the size of the ventricles and the Left Ventricular Ejection Fraction (LVEF).

A key research limitation is that the primary evidence base applies only to those post-MI patients who already had a measurable reduced LVEF. The evidence is based largely on a single trial, and dedicated head-to-head comparative evidence against other similar treatments in this exact context is limited.


Areas of Research Uncertainty and Gaps

Specific research limitations include the fact that long-term effects are not fully established for all uses, particularly in uncomplicated hypertension. Additionally, the scientific literature includes discussions about the design of comparator trials—meaning comparative evidence is lacking for certain potential pairings. Characterizing long-term outcomes in all different types of heart failure patients remains an area of ongoing research.

Key Studies & References

  1. Carvedilol: MedlinePlus Drug Information (General Evidence Summary)

Frequently Asked Questions (FAQ)

Common questions about Karvil (FAQ)


Q: Is Karvil the same kind of medicine as [similar common drug name]?

Karvil is officially classified as an alpha- and beta-adrenoreceptor blocker. Unlike some older beta-blockers that only block beta receptors, official documents describe Karvil as having a dual action. This means it works both to slow the heart rate and to promote the relaxation of blood vessels, which is a documented benefit that distinguishes it from pure beta-blockers.

Q: Can Karvil affect my mood or energy levels?

Official adverse reaction reports indicate that fatigue (a feeling of tiredness or low energy) is a common side effect of Karvil. Sleep disturbances have also been documented. The development of any changes in general well-being is important information for a healthcare provider.

Q: Are there different strengths or doses of Karvil available?

According to the official product information, Karvil immediate-release tablets are generally available in four different strengths: 3.125 mg, 6.25 mg, 12.5 mg, and 25 mg tablets. This range of strengths supports the systematic, gradual dosing adjustments described in the official instructions.

Q: Are the side effects of Karvil usually temporary?

Regulatory documents state that certain common side effects, such as dizziness and lightheadedness, tend to be transient. These are documented as being more likely to occur when treatment is initiated or when the dose is being increased. Other side effects may or may not lessen over time.

Q: Why did my doctor choose Karvil instead of other options?

Karvil's selection is based on its specific mechanism of action, which involves blocking both alpha and beta receptors. Official sources highlight that its dual-action approach is utilized when the clinical goal involves both moderating heart rate and achieving blood vessel dilation. Its use is based on established clinical guidelines for certain cardiovascular conditions.

Q: Does Karvil interact with supplements, like vitamins or herbal products?

Official labeling documents confirm that some multivitamins containing minerals may interact with Karvil. This interaction could potentially decrease the medicine's effects. Official product information suggests that administration of Karvil and mineral-containing supplements may need to be separated by at least two hours.

Q: Why do official documents mention 'contraindications' for Karvil?

Contraindications are conditions where the risk of taking a medicine clearly outweighs any potential medical benefit. For Karvil, contraindications are listed in regulatory documents to prevent use in people with serious conditions, such as severe liver impairment or certain respiratory illnesses like bronchial asthma, where the medicine has the potential to lead to a severe adverse outcome.

Q: How does Karvil compare to older medicines for the same condition (without discussing effectiveness)?

The official pharmacological classification describes Karvil as having a dual mechanism. This means it functions as both a beta-blocker and an alpha-1 blocker. This dual action is a documented difference from older, pure beta-blockers that only block beta receptors in the body.

Q: Can I drive or operate machinery while taking Karvil?

Regulatory warnings indicate that patients should use caution when driving or operating hazardous machinery. This caution is heightened during the initial period of treatment or following a dose increase due to the documented risk of dizziness or fainting.

Q: Are there any patient registries or long-term studies being conducted on Karvil?

While specific, ongoing patient registries may not be publicly listed, regulatory bodies have issued formal requests for post-market studies. This is a standard process to gather more long-term data on the medicine's safety and effectiveness, particularly in specific subgroups like children.

Q: Are there special restrictions for young adults using Karvil?

Official regulatory labels state that the effectiveness of Karvil in patients younger than 18 years of age has not been fully established. Use in this group must be guided by the medical professional, as the evidence base is not fully established.

Q: How do I know if the side effects I'm having are serious with Karvil?

Official adverse reaction documents list certain signs that may indicate a serious reaction. These include a light-headed feeling or fainting, slow or uneven heartbeats, or new or worsening swelling or rapid weight gain. If an individual experiences these symptoms, they are documented as requiring immediate medical evaluation.

Q: Does the evidence for Karvil show a consistent benefit across different groups of people?

Clinical studies reviewed by regulatory bodies indicate limitations for certain subgroups. For instance, evidence is noted as being limited for children and adolescents. Additionally, the primary evidence for heart benefits applies mainly to patients with documented reduced heart function (low LVEF).

Q: Are there any required lab tests or monitoring while taking Karvil?

Official warnings and precautions state that monitoring is required for blood pressure and heart rate. Additionally, patients with diabetes require close monitoring of their blood glucose levels. This is because Karvil may have the potential to mask the typical symptoms of low blood sugar.

Q: What's the difference between the 'active' and 'inactive' ingredients in Karvil?

The active ingredient, Carvedilol, is the component of the medicine that produces the intended medical effect on the body. The inactive ingredients, such as excipients and coloring agents, are used to form the physical tablet and do not provide a medical benefit.

Q: How quickly can I expect Karvil to start working?

Official clinical pharmacology information indicates that for the management of high blood pressure, the full blood pressure-lowering effect is typically observed within seven to fourteen days. The time it takes to see the full effect will depend on the condition being addressed and the patient's individualized regimen.

Q: Does Karvil cause weight gain or loss?

Weight gain is listed as a common adverse reaction, particularly in patients being treated for heart failure. Official documents advise that rapid or significant weight gain is important information for a healthcare provider, as it could be a sign of worsening fluid retention.

Q: Are there any common foods or drinks I need to avoid while on Karvil?

Regulatory information indicates that Karvil must be taken with food. Official product information suggests that administration of Karvil and mineral-containing supplements may need to be separated. Alcohol may also increase the blood pressure-lowering effects of the medicine.

Q: Will Karvil show up on a standard drug test?

Karvil is not classified as a controlled substance by the US Drug Enforcement Administration (DEA), meaning it is not generally a target of standard abuse-screening drug tests. However, patients who undergo drug testing generally provide full disclosure of all medications taken to the testing facility.

Q: How long does Karvil stay in your system after the last dose?

Pharmacokinetic data from regulatory documents indicate that the half-life of Carvedilol is typically between seven and ten hours. This measurement describes the time it takes for the concentration of the medicine in the body to decrease by half.

Q: Is Karvil safe for older adults or seniors?

Official regulatory data reports that no overall differences in safety or effectiveness were observed between older and younger adult subjects. However, older patients with high blood pressure may experience dizziness slightly more often. The occurrence of dizziness is a documented safety point for this population.

Q: Is there a generic version of Karvil yet?

Yes, Karvil is the brand name for the active ingredient Carvedilol. According to government drug information resources, Carvedilol is available as an FDA-approved generic medication.

Q: Does Karvil have a 'Black Box Warning' or special safety alerts?

The official FDA label for Karvil does not contain a Black Box Warning, which is the most serious warning category. However, the drug label does include several important warnings, notably regarding the risks associated with abruptly discontinuing the medication.

Q: Can Karvil be cut in half or crushed?

Regulatory instructions for immediate-release tablets, such as Karvil, state that the tablets should be swallowed whole. They should not be crushed or chewed. This requirement helps maintain the proper dose and rate of absorption documented in the official labeling.

Q: Will Karvil make me dependent or addicted?

Karvil is not classified as a controlled substance by regulatory bodies. It is not generally associated with the type of physical dependence or addiction seen with controlled prescription medicines.

Q: What should I know about taking Karvil with alcohol?

Official drug interaction information indicates that consuming alcohol while taking Karvil may increase the medicine's effect of lowering blood pressure. This additive effect can increase the risk of symptoms like dizziness, lightheadedness, or fainting.

Q: What is the risk of overdose with Karvil?

Overdose on Karvil is associated with an increased risk of severe, uncontrolled medical events. These include profound hypotension (dangerously low blood pressure) and severe bradycardia (a dangerously slow heart rate). If an overdose is suspected, the resulting severe symptoms are documented as requiring immediate medical evaluation.

Q: What should be done if I miss a dose of Karvil?

Official patient information states that if a dose is missed, it should be taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Official instructions state that doses should not be doubled to compensate for a missed dose.

How should Karvil be stored and disposed of?

Karvil (Carvedilol) tablets require specific environmental controls to maintain their stability, as mandated by official labeling.

Storage Requirements

The medication must be stored at a temperature not exceeding 30°C, with US labeling specifying a Controlled Room Temperature range of 20, C to 25, C (68, F to 77, F). The tablets must be kept dry and protected from moisture and light. It is required to keep Karvil in its original container, which must remain tightly closed.

Child-Safety Storage

Regulatory documents state that Karvil must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements. The medication is not recommended for flushing down the sink or toilet and should be mixed with an undesirable substance before being placed in household trash if a take-back program is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Karvil found in:

A-Z Index: